JNJ-64417161 (TD-8236)
Undisclosed Inflammatory Disease
Out-licensedLicensed to Janssen
Key Facts
Indication
Undisclosed Inflammatory Disease
Phase
Out-licensed
Status
Licensed to Janssen
Company
About Theravance Biopharma
Theravance Biopharma is a commercial-stage biotech focused on transforming treatment for serious respiratory diseases through organ-selective medicines. Its core achievement is the FDA approval and commercialization of YUPELRI® (revefenacin) for COPD, validating its multivalent pharmacology platform. The company's strategy involves leveraging this platform to advance a pipeline of targeted respiratory therapeutics while managing commercial execution through a partnership with Viatris.
View full company profile